Guidance, NICE advice and quality standards in development | Guidance

Showing 181 to 190 of 392

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]	Highly specialised technology	TBC
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]	Technology appraisal guidance	TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]	Technology appraisal guidance	TBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863	Technology appraisal guidance	TBC
Linzagolix for treating symptoms of endometriosis [ID6357]	Technology appraisal guidance	25 June 2025
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]	Technology appraisal guidance	TBC